메뉴 건너뛰기




Volumn 126, Issue 1, 2010, Pages 247-255

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer

Author keywords

EGFR; Gefitinib; Lung cancer; Mutation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; NONERLOTINIB; PACLITAXEL; PLATINUM DERIVATIVE; PREMETREXED; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

EID: 73449123757     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24657     Document Type: Article
Times cited : (53)

References (41)
  • 2
    • 0028843552 scopus 로고
    • Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
    • Non-small Cell Lung Cancer Collaborative Group
    • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311: 899-909.
    • (1995) BMJ , vol.311 , pp. 899-909
  • 6
    • 0034600849 scopus 로고    scopus 로고
    • The erbB signaling network: Receptor heterodimerization in development and cancer
    • Olayioye MA, Neve RM, Lane HA, Hynes NE. The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
    • (2000) EMBO J , vol.19 , pp. 3159-3167
    • Olayioye, M.A.1    Neve, R.M.2    Lane, H.A.3    Hynes, N.E.4
  • 9
    • 33746789922 scopus 로고    scopus 로고
    • Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
    • Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6.
    • (2006) J Clin Oncol , vol.24 , pp. 3340-3346
    • Inoue, A.1    Suzuki, T.2    Fukuhara, T.3    Maemondo, M.4    Kimura, Y.5    Morikawa, N.6    Watanabe, H.7    Saijo, Y.8    Nukiwa, T.9
  • 13
    • 10844231985 scopus 로고    scopus 로고
    • Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications
    • Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
    • (2004) Cancer Res , vol.64 , pp. 8919-8923
    • Kosaka, T.1    Yatabe, Y.2    Endoh, H.3    Kuwano, H.4    Takahashi, T.5    Mitsudomi, T.6
  • 14
    • 34548052247 scopus 로고    scopus 로고
    • Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature
    • Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, Chen Z, Gonzalez KD, Sommer SS. Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 2007;28:760-70.
    • (2007) Hum Mutat , vol.28 , pp. 760-770
    • Gu, D.1    Scaringe, W.A.2    Li, K.3    Saldivar, J.S.4    Hill, K.A.5    Chen, Z.6    Gonzalez, K.D.7    Sommer, S.S.8
  • 15
    • 29144496089 scopus 로고    scopus 로고
    • Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy
    • Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 2006;42:17-23.
    • (2006) Eur J Cancer , vol.42 , pp. 17-23
    • Chan, S.K.1    Gullick, W.J.2    Hill, M.E.3
  • 20
    • 58949088423 scopus 로고    scopus 로고
    • Lung Oncology Group in Kyushu, Japan. A phase II trial of gefitinib monotherapy in chemotherapy-naÿve patients of 75 years or older with advanced non-small cell lung cancer
    • Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y; Lung Oncology Group in Kyushu, Japan. A phase II trial of gefitinib monotherapy in chemotherapy-naÿve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:1166-71.
    • (2008) J Thorac Oncol , vol.3 , pp. 1166-1171
    • Ebi, N.1    Semba, H.2    Tokunaga, S.J.3    Takayama, K.4    Wataya, H.5    Kuraki, T.6    Yamamoto, H.7    Akamine, S.J.8    Okamoto, I.9    Nakanishi, Y.10
  • 22
    • 73449127842 scopus 로고    scopus 로고
    • Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, Jiang H, Watkins C, Armour A, Fukuoka M. Phase III, randomized, open-label, first line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) (IPASS) [Abstract LBA2]. Ann Oncol 2008;19(suppl 8):viii1.
    • Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, Jiang H, Watkins C, Armour A, Fukuoka M. Phase III, randomized, open-label, first line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) (IPASS) [Abstract LBA2]. Ann Oncol 2008;19(suppl 8):viii1.
  • 25
    • 31544440171 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
    • Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP, Yang PC. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006;118:963-9.
    • (2006) Int J Cancer , vol.118 , pp. 963-969
    • Shih, J.Y.1    Gow, C.H.2    Yu, C.J.3    Yang, C.H.4    Chang, Y.L.5    Tsai, M.F.6    Hsu, Y.C.7    Chen, K.Y.8    Su, W.P.9    Yang, P.C.10
  • 28
    • 20244388126 scopus 로고    scopus 로고
    • Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
    • Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
    • (2005) J Clin Oncol , vol.23 , pp. 2513-2520
    • Mitsudomi, T.1    Kosaka, T.2    Endoh, H.3    Horio, Y.4    Hida, T.5    Mori, S.6    Hatooka, S.7    Shinoda, M.8    Takahashi, T.9    Yatabe, Y.10
  • 29
    • 51049116207 scopus 로고    scopus 로고
    • Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
    • Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clinical Cancer Res 2008;14:4877-82.
    • (2008) Clinical Cancer Res , vol.14 , pp. 4877-4882
    • Wu, J.Y.1    Wu, S.G.2    Yang, C.H.3    Gow, C.H.4    Chang, Y.L.5    Yu, C.J.6    Shih, J.Y.7    Yang, P.C.8
  • 30
    • 41549125361 scopus 로고    scopus 로고
    • Multicenter phase II trial of gefitinib firstline therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
    • D'Addario G, Rauch D, Stupp R, Pless M, Stahel R, Mach N, Jost L, Widmer L, Tapia C, Bihl M, Mayer M, Ribi K, et al. Multicenter phase II trial of gefitinib firstline therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008;19:739-45.
    • (2008) Ann Oncol , vol.19 , pp. 739-745
    • D'Addario, G.1    Rauch, D.2    Stupp, R.3    Pless, M.4    Stahel, R.5    Mach, N.6    Jost, L.7    Widmer, L.8    Tapia, C.9    Bihl, M.10    Mayer, M.11    Ribi, K.12
  • 35
    • 56749178852 scopus 로고    scopus 로고
    • Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment
    • Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008; 19:2039-42.
    • (2008) Ann Oncol , vol.19 , pp. 2039-2042
    • Lee, D.H.1    Kim, S.W.2    Suh, C.3    Yoon, D.H.4    Yi, E.J.5    Lee, J.S.6
  • 37
    • 41949119173 scopus 로고    scopus 로고
    • Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations
    • Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008;26:1182-4.
    • (2008) J Clin Oncol , vol.26 , pp. 1182-1184
    • Costa, D.B.1    Schumer, S.T.2    Tenen, D.G.3    Kobayashi, S.4
  • 40
    • 20044364933 scopus 로고    scopus 로고
    • EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
    • Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65.
    • (2005) J Clin Oncol , vol.23 , pp. 857-865
    • Marchetti, A.1    Martella, C.2    Felicioni, L.3    Barassi, F.4    Salvatore, S.5    Chella, A.6    Camplese, P.P.7    Iarussi, T.8    Mucilli, F.9    Mezzetti, A.10    Cuccurullo, F.11    Sacco, R.12
  • 41
    • 24944497744 scopus 로고    scopus 로고
    • Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
    • (2005) J Clin Oncol , vol.23 , pp. 5900-5909
    • Eberhard, D.A.1    Johnson, B.E.2    Amler, L.C.3    Goddard, A.D.4    Heldens, S.L.5    Herbst, R.S.6    Ince, W.L.7    Jänne, P.A.8    Januario, T.9    Johnson, D.H.10    Klein, P.11    Miller, V.A.12


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.